Asset
BARZOLVOLIMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04146129 | phase1 | completed | 2019-10-29 | 2020-04-06 | Celldex Therapeutics | A Phase 1 Study of CDX-0159 |
| NCT05031624 | phase1 | completed | 2021-08-30 | 2022-01-14 | Celldex Therapeutics | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects |
| NCT05368285 | phase2 | completed | 2022-05-19 | 2023-09-28 | Celldex Therapeutics | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria |
| NCT06445023 | phase3 | active_not_recruiting | 2024-07-11 | 2026-10-01 | Celldex Therapeutics | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria |
| NCT06455202 | phase3 | active_not_recruiting | 2024-07-19 | 2026-10-01 | Celldex Therapeutics | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) |
FDA applications (0)
This company has no applications containing this asset.